Company news

Alterity Therapeutics Ltd. news in 2026

Alterity Therapeutics Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Notice of General Meeting/Proxy Form

April 29, 2026

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

April 27, 2026

Alterity Receives Positive FDA Feedback on CMC Meeting

April 26, 2026

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

April 22, 2026

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

April 17, 2026

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

April 16, 2026

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

April 15, 2026

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

March 30, 2026

Alterity Receives Positive FDA Feedback From Type C Meeting

March 29, 2026

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

March 9, 2026

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

March 4, 2026

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

March 2, 2026

Half Yearly Report and Accounts

February 25, 2026

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

January 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

January 21, 2026

← Newer news releases

Decks in 2026